Study on the effect
of topical Nepafenac 0.1% w/v in preventing Macular edema after cataract surgery
in patients with diabetes
Ramalingam Kothai, Kalaimamani Ezhilvendhan, Iyyappan Saranya, Sivamurugan Rajesh
Kanna and Vijayan Roshini
Res. J. Biotech.; Vol. 20(11); 49-53;
doi: https://doi.org/10.25303/2011rjbt049053; (2025)
Abstract
Cystoid macular edema (CME) is one of the major problems in diabetes patients after
cataract surgery, which leads to fluid accumulation within the macular region. This
clinical study aims to evaluate the effect of topical nepafenac 0.1% in preventing
macular edema. The prospective interventional clinical study was conducted in the
Department of Ophthalmology of a tertiary care hospital at Salem for a period of
six months from Jan 2024 to June 2024. Investigations include random blood sugar
(RBS), visual acuity, macular thickness and intraocular pressure (IOP) done on patients.
50 patients received sterile ophthalmic suspensions of 0.1% nepafenac and 50 patients
received 0.5% carboxy methyl cellulose as placebo, both used thrice in a day before
and after cataract surgery. Optical coherence tomography (OCT) was performed both
pre-operatively before cataract surgery and up to 90 days after post-operative.
The outcome of this study shows a gradual decrease in macular thickness and, an
increase in visual acuity. This study negotiates that nepafenac 0.1% was effective
in preventing macular edema. It is considered to be safe and no complications were
developed in patients subjected to nepafenac after cataract surgery in diabetes
patients.
